HLB Life Science Co Ltd
067630
Company Profile
Business description
HLB Life Science Co Ltd and its subsidiaries are engaged in the medicare business, bio development business, medical device business, and drug distribution business. The company is a medical device for in vitro diagnostics.The main business is the Medicare business, which includes foot and manufacturing, quasi-drug component development, and finished product consignment production.
Contact
3-10th Floor, Pangyo Seven Venture Valley 1-danji
15, Pangyo-ro 228 beon-gil
Gyeonggi-do
Seongnam-si
KORT: +82 226276700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2026
Employees
187
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,414.35 | 1.48 | 0.01% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |